{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:03:59Z","timestamp":1791288239315,"version":"4.3.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T00:00:00Z","timestamp":1510272000000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1139937"],"award-info":[{"award-number":["OPP1139937"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["EB-000244"],"award-info":[{"award-number":["EB-000244"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Max Planck Research Award, Award Ltr Dtd. 2\/11\/08, Alexander von Humboldt-Stiftung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.xphs.2016.09.015","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T01:46:57Z","timestamp":1476928017000},"page":"3471-3482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Past, Present, and Future Drug Delivery Systems for Antiretrovirals"],"prefix":"10.1016","volume":"105","author":[{"given":"Ameya R.","family":"Kirtane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Traverso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2016.09.015_bib1","series-title":"Global Summary of the AIDS Epidemic 2014","year":"2016"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/84564","article-title":"The natural history of HIV-1 infection in Africa","volume":"7","author":"Morgan","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.xphs.2016.09.015_bib3","series-title":"Global Statistics Fact Sheet 2015","year":"2016"},{"issue":"21","key":"10.1016\/j.xphs.2016.09.015_bib4","first-page":"250","article-title":"Pneumocystis pneumonia\u2013Los Angeles","volume":"30","year":"1981","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"25","key":"10.1016\/j.xphs.2016.09.015_bib5","first-page":"305","article-title":"Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men\u2013New York City and California","volume":"30","year":"1981","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4599","key":"10.1016\/j.xphs.2016.09.015_bib6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barre-Sinoussi","year":"1983","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.xphs.2016.09.015_bib7","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMp038194","article-title":"The discovery of HIV as the cause of AIDS","volume":"349","author":"Gallo","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4648","key":"10.1016\/j.xphs.2016.09.015_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1126\/science.6200936","article-title":"Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS","volume":"224","author":"Gallo","year":"1984","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib9","doi-asserted-by":"crossref","first-page":"a006841","DOI":"10.1101\/cshperspect.a006841","article-title":"Origins of HIV and the AIDS pandemic","volume":"1","author":"Sharp","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5178","key":"10.1016\/j.xphs.2016.09.015_bib10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.7915856","article-title":"Reduced rate of disease development after HIV-2 infection as compared to HIV-1","volume":"265","author":"Marlink","year":"1994","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.xphs.2016.09.015_bib11","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM200106073442306","article-title":"AIDS\u2013the first 20 years","volume":"344","author":"Sepkowitz","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.xphs.2016.09.015_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/nrmicro3132","article-title":"Past, present and future: 30 years of HIV research","volume":"11","author":"Barre-Sinoussi","year":"2013","journal-title":"Nat Rev Microbiol"},{"issue":"7193","key":"10.1016\/j.xphs.2016.09.015_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/453289a","article-title":"25 years of HIV","volume":"453","author":"Fauci","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2016.09.015_bib14","series-title":"The Search for Antiviral Drugs: Case Histories from Concept to Clinic","first-page":"23","article-title":"Discovery and development of zidovudine as the cornerstone of therapy to control human immunodeficiency virus infection","author":"Pattishall","year":"1993"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.xphs.2016.09.015_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"10","key":"10.1016\/j.xphs.2016.09.015_bib17","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.drudis.2014.05.012","article-title":"An analysis of FDA-approved drugs for infectious disease: HIV\/AIDS drugs","volume":"19","author":"Kinch","year":"2014","journal-title":"Drug Discov Today"},{"issue":"12","key":"10.1016\/j.xphs.2016.09.015_bib18","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.xphs.2016.09.015_bib19","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11904-011-0078-4","article-title":"Preexposure prophylaxis for HIV prevention","volume":"8","author":"Kelesidis","year":"2011","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/COH.0b013e32833a6c32","article-title":"Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update","volume":"5","author":"Granich","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/01.qai.0000179459.31562.16","article-title":"Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras","volume":"41","author":"Crum","year":"2006","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"7213","key":"10.1016\/j.xphs.2016.09.015_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nature07352","article-title":"Challenges in the development of an HIV-1 vaccine","volume":"455","author":"Barouch","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1728-4465.2004.00004.x","article-title":"Condom promotion for AIDS prevention in the developing world: is it working?","volume":"35","author":"Hearst","year":"2004","journal-title":"Stud Fam Plann"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1462-5822.2005.00516.x","article-title":"The ins and outs of HIV replication","volume":"7","author":"Gomez","year":"2005","journal-title":"Cell Microbiol"},{"issue":"7286","key":"10.1016\/j.xphs.2016.09.015_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature08757","article-title":"Targeting early infection to prevent HIV-1 mucosal transmission","volume":"464","author":"Haase","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"issue":"6593","key":"10.1016\/j.xphs.2016.09.015_bib28","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"issue":"6594","key":"10.1016\/j.xphs.2016.09.015_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/382829a0","article-title":"The lymphocyte chemoattractant SDF-1 is a ligand for LESTR\/fusin and blocks HIV-1 entry","volume":"382","author":"Bleul","year":"1996","journal-title":"Nature"},{"issue":"6594","key":"10.1016\/j.xphs.2016.09.015_bib30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/382833a0","article-title":"The CXC chemokine SDF-1 is the ligand for LESTR\/fusin and prevents infection by T-cell-line-adapted HIV-1","volume":"382","author":"Oberlin","year":"1996","journal-title":"Nature"},{"issue":"4820","key":"10.1016\/j.xphs.2016.09.015_bib31","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.3629244","article-title":"Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1","volume":"237","author":"Kowalski","year":"1987","journal-title":"Science"},{"issue":"4743","key":"10.1016\/j.xphs.2016.09.015_bib32","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1126\/science.2418504","article-title":"Characterization of highly immunogenic p66\/p51 as the reverse transcriptase of HTLV-III\/LAV","volume":"231","author":"di Marzo Veronese","year":"1986","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.xphs.2016.09.015_bib33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2174\/1568026043388547","article-title":"Structure and function of HIV-1 integrase","volume":"4","author":"Chiu","year":"2004","journal-title":"Curr Top Med Chem"},{"issue":"11","key":"10.1016\/j.xphs.2016.09.015_bib34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrmicro2223","article-title":"Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs","volume":"7","author":"Coiras","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"10.1016\/j.xphs.2016.09.015_bib35","doi-asserted-by":"crossref","first-page":"a006924","DOI":"10.1101\/cshperspect.a006924","article-title":"HIV-1 assembly, budding, and maturation","volume":"2","author":"Sundquist","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib36","doi-asserted-by":"crossref","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs","volume":"1","author":"De Clercq","year":"2002","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.antiviral.2009.09.008","article-title":"Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009)","volume":"85","author":"de Bethune","year":"2009","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1006\/jmbi.2001.4648","article-title":"The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance","volume":"309","author":"Hsiou","year":"2001","journal-title":"J\u00a0Mol Biol"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib40","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J\u00a0Med Chem"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nrd1660","article-title":"Integrase inhibitors to treat HIV\/AIDS","volume":"4","author":"Pommier","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib42","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.coviro.2012.08.007","article-title":"The development of novel HIV integrase inhibitors and the problem of drug resistance","volume":"2","author":"Wainberg","year":"2012","journal-title":"Curr Opin Virol"},{"issue":"18","key":"10.1016\/j.xphs.2016.09.015_bib43","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1086\/520847","article-title":"Tipranavir: a new option for the treatment of drug-resistant HIV infection","volume":"45","author":"Temesgen","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.antiviral.2013.03.017","article-title":"Entry inhibitors and their use in the treatment of HIV-1 infection","volume":"98","author":"Haqqani","year":"2013","journal-title":"Antivir Res"},{"key":"10.1016\/j.xphs.2016.09.015_bib46","first-page":"5447","article-title":"Maraviroc: a review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"110","key":"10.1016\/j.xphs.2016.09.015_bib47","first-page":"252","article-title":"Maraviroc first-line therapy for HIV infection. Too risky","volume":"19","year":"2010","journal-title":"Prescrire Int"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.xphs.2016.09.015_bib49","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xphs.2016.09.015_bib50","series-title":"2016 Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2016"},{"issue":"91","key":"10.1016\/j.xphs.2016.09.015_bib51","doi-asserted-by":"crossref","first-page":"91ra63","DOI":"10.1126\/scitranslmed.3002304","article-title":"A\u00a0critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs","volume":"3","author":"Shen","year":"2011","journal-title":"Sci Transl Med"},{"issue":"9635","key":"10.1016\/j.xphs.2016.09.015_bib52","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2016.09.015_bib53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.med.53.082901.104024","article-title":"The challenge of viral reservoirs in HIV-1 infection","volume":"53","author":"Blankson","year":"2002","journal-title":"Annu Rev Med"},{"issue":"8","key":"10.1016\/j.xphs.2016.09.015_bib54","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/378301","article-title":"Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance","volume":"37","author":"Sethi","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"7544","key":"10.1016\/j.xphs.2016.09.015_bib56","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/519S19a","article-title":"Perspective: special delivery for the gut","volume":"519","author":"Traverso","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib57","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s10461-013-0429-9","article-title":"Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials","volume":"17","author":"Amico","year":"2013","journal-title":"AIDS Behav"},{"issue":"5996","key":"10.1016\/j.xphs.2016.09.015_bib58","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib59","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib60","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib61","doi-asserted-by":"crossref","first-page":"e28238","DOI":"10.1371\/journal.pone.0028238","article-title":"Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study","volume":"7","author":"Eisingerich","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.xphs.2016.09.015_bib62","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00002030-199714000-00002","article-title":"Potential factors affecting adherence with HIV therapy","volume":"11","author":"Mehta","year":"1997","journal-title":"AIDS"},{"issue":"13","key":"10.1016\/j.xphs.2016.09.015_bib63","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1097\/00002030-199909100-00021","article-title":"Sociodemographic and psychological variables influencing adherence to antiretroviral therapy","volume":"13","author":"Gordillo","year":"1999","journal-title":"AIDS"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2016.09.015_bib64","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1097\/QAD.0000000000000252","article-title":"Interventions to improve adherence to antiretroviral therapy: a rapid systematic review","volume":"28","author":"Chaiyachati","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.xphs.2016.09.015_bib65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2458-7-104","article-title":"A\u00a0review of health behaviour theories: how useful are these for developing interventions to promote long-term medication adherence for TB and HIV\/AIDS?","volume":"7","author":"Munro","year":"2007","journal-title":"BMC Public Health"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2016.09.015_bib66","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1086\/313849","article-title":"Factors affecting adherence to antiretroviral therapy","volume":"30","author":"Chesney","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.xphs.2016.09.015_bib67","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.amjmed.2006.08.033","article-title":"Fixed-dose combinations improve medication compliance: a meta-analysis","volume":"120","author":"Bangalore","year":"2007","journal-title":"Am J Med"},{"issue":"15","key":"10.1016\/j.xphs.2016.09.015_bib68","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJM199704103361507","article-title":"Sexual transmission of HIV","volume":"336","author":"Royce","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"6830","key":"10.1016\/j.xphs.2016.09.015_bib69","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bmj.304.6830.809","article-title":"Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV","volume":"304","year":"1992","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1258\/0956462001915606","article-title":"An acceptability study of female-controlled methods of protection against HIV and STDs in south-western Uganda","volume":"11","author":"Pool","year":"2000","journal-title":"Int J STD AIDS"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib71","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1089\/jwh.2007.0529","article-title":"An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population","volume":"17","author":"Smith","year":"2008","journal-title":"J\u00a0Womens Health (larchmt)"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00137696-200604010-00002","article-title":"Potential use of vaginal rings for prevention of heterosexual transmission of HIV","volume":"4","author":"Woolfson","year":"2006","journal-title":"Am J Drug Deliv"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.09.015_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.03.012","article-title":"Gels as vaginal drug delivery systems","volume":"318","author":"das Neves","year":"2006","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib74","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00002030-199305000-00018","article-title":"Barrier contraceptive use and HIV infection among high-risk women in Cameroon","volume":"7","author":"Zekeng","year":"1993","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-009-9082-7","article-title":"Vaginal drug delivery systems for HIV prevention","volume":"11","author":"Rohan","year":"2009","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.xphs.2016.09.015_bib76","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/jps.21192","article-title":"Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products","volume":"97","author":"Sassi","year":"2008","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2016.09.015_bib77","first-page":"1","article-title":"Efficacy of tenofovir 1% vaginal gel in reducing the risk of HIV-1 and HSV-2 infection","volume":"7","author":"McConville","year":"2014","journal-title":"Clin Med Insights Womens Health"},{"issue":"Suppl 1","key":"10.1016\/j.xphs.2016.09.015_bib78","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.antiviral.2010.09.003","article-title":"Advances in microbicide vaginal rings","volume":"88","author":"Malcolm","year":"2010","journal-title":"Antivir Res"},{"issue":"4 Suppl","key":"10.1016\/j.xphs.2016.09.015_bib79","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.ajog.2004.01.056","article-title":"New delivery systems in contraception: vaginal rings","volume":"190","author":"Johansson","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib80","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.contraception.2010.04.012","article-title":"Contraceptive vaginal rings: a review","volume":"82","author":"Brache","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.xphs.2016.09.015_bib81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2016.04.035","article-title":"A\u00a0novel approach to administration of peptides in women: systemic absorption of a GnRH agonist via transvaginal ring delivery system","volume":"233","author":"Kimball","year":"2016","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2016.09.015_bib82","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","author":"Baeten","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.xphs.2016.09.015_bib83","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1002\/jps.21331","article-title":"Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1","volume":"97","author":"Gupta","year":"2008","journal-title":"J\u00a0Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib84","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/jac\/dki326","article-title":"Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings","volume":"56","author":"Malcolm","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib85","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1211\/jpp.59.2.0007","article-title":"Characterization of silicone elastomer vaginal rings containing HIV microbicide TMC120 by Raman spectroscopy","volume":"59","author":"Bell","year":"2007","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.09.015_bib86","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.06.026","article-title":"Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide","volume":"325","author":"Woolfson","year":"2006","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib87","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/aid.2008.0184","article-title":"Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring","volume":"25","author":"Romano","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib88","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/QAI.0b013e3181acb536","article-title":"Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women","volume":"51","author":"Nel","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib89","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/AAC.05721-11","article-title":"Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings","volume":"56","author":"Johnson","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2016.09.015_bib90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2015.12.035","article-title":"Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral release","volume":"224","author":"Teller","year":"2015","journal-title":"J\u00a0Control Release"},{"issue":"10","key":"10.1016\/j.xphs.2016.09.015_bib91","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1002\/jps.24551","article-title":"An intravaginal ring for the simultaneous delivery of an HIV-1 maturation inhibitor and reverse-transcriptase inhibitor for prophylaxis of HIV transmission","volume":"104","author":"Ugaonkar","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib92","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2012.08.033","article-title":"Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir","volume":"163","author":"Clark","year":"2012","journal-title":"J\u00a0Control Release"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib93","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13346-011-0027-1","article-title":"Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine","volume":"1","author":"Kaur","year":"2011","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib94","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2009.11.007","article-title":"Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir","volume":"39","author":"Johnson","year":"2010","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib95","doi-asserted-by":"crossref","first-page":"e88509","DOI":"10.1371\/journal.pone.0088509","article-title":"Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy","volume":"9","author":"Clark","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib96","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/AAC.05662-11","article-title":"Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring","volume":"56","author":"Moss","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.xphs.2016.09.015_bib97","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/jps.23208","article-title":"An intravaginal ring for the simultaneous delivery of multiple drugs","volume":"101","author":"Baum","year":"2012","journal-title":"J\u00a0Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib98","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/COH.0000000000000002","article-title":"Long-acting injectable antiretrovirals for HIV treatment and prevention","volume":"8","author":"Spreen","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"10.1016\/j.xphs.2016.09.015_bib99","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/cid\/ciu1159","article-title":"The clinical role and cost-effectiveness of long-acting antiretroviral therapy","volume":"60","author":"Ross","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/COH.0000000000000219","article-title":"The promise and pitfalls of long-acting injectable agents for HIV prevention","volume":"11","author":"Landovitz","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib101","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nm0414-323","article-title":"Long-acting HIV drugs advanced to overcome adherence challenge","volume":"20","author":"Dolgin","year":"2014","journal-title":"Nat Med"},{"issue":"6175","key":"10.1016\/j.xphs.2016.09.015_bib102","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1126\/science.343.6175.1067","article-title":"Virology. A bid to thwart HIV with shot of long-lasting drug","volume":"343","author":"Cohen","year":"2014","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib103","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib104","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejpb.2009.03.006","article-title":"Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment","volume":"72","author":"Baert","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib105","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01529-09","article-title":"Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation","volume":"54","author":"van 't Klooster","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib106","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/COH.0000000000000160","article-title":"Long-acting rilpivirine for HIV prevention","volume":"10","author":"Jackson","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib107","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/clpt.2014.118","article-title":"A\u00a0compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis","volume":"96","author":"Jackson","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"6175","key":"10.1016\/j.xphs.2016.09.015_bib108","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1126\/science.1248707","article-title":"Long-acting integrase inhibitor protects macaques from intrarectal simian\/human immunodeficiency virus","volume":"343","author":"Andrews","year":"2014","journal-title":"Science"},{"issue":"270","key":"10.1016\/j.xphs.2016.09.015_bib109","doi-asserted-by":"crossref","first-page":"270ra275","DOI":"10.1126\/scitranslmed.3010297","article-title":"The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge","volume":"7","author":"Radzio","year":"2015","journal-title":"Sci Transl Med"},{"issue":"270","key":"10.1016\/j.xphs.2016.09.015_bib110","doi-asserted-by":"crossref","first-page":"270ra274","DOI":"10.1126\/scitranslmed.3010298","article-title":"A\u00a0long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib111","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/QAI.0000000000000301","article-title":"GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects","volume":"67","author":"Spreen","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib112","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/QAI.0000000000000365","article-title":"Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults","volume":"67","author":"Spreen","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib113","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1128\/AAC.03906-14","article-title":"Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants","volume":"59","author":"Cortez","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib114","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/jac\/dkw042","article-title":"A\u00a0long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges","volume":"71","author":"Kovarova","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib115","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"7","key":"10.1016\/j.xphs.2016.09.015_bib116","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1128\/AAC.00656-15","article-title":"Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis","volume":"59","author":"Gunawardana","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5919","key":"10.1016\/j.xphs.2016.09.015_bib117","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1165706","article-title":"The challenge of finding a cure for HIV infection","volume":"323","author":"Richman","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib118","first-page":"3","article-title":"Reservoirs of HIV-1 in\u00a0vivo: implications for antiretroviral therapy","volume":"5","author":"Saksena","year":"2003","journal-title":"AIDS Rev"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib119","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","article-title":"The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors","volume":"101","author":"Kim","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00042560-199901010-00006","article-title":"Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1\u2013infected patients with and without AIDS dementia complex","volume":"20","author":"Aweeka","year":"1999","journal-title":"J\u00a0Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib121","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jama.280.1.67","article-title":"Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy","volume":"280","author":"Schrager","year":"1998","journal-title":"JAMA"},{"issue":"5443","key":"10.1016\/j.xphs.2016.09.015_bib122","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1126\/science.286.5443.1353","article-title":"Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells","volume":"286","author":"Zhang","year":"1999","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib123","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/157016208785861195","article-title":"Cellular reservoirs of HIV-1 and their role in viral persistence","volume":"6","author":"Alexaki","year":"2008","journal-title":"Curr HIV Res"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib124","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3390\/v7041578","article-title":"Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?","volume":"7","author":"Abbas","year":"2015","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0166-3542(02)00052-9","article-title":"Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir","volume":"55","author":"Aquaro","year":"2002","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib126","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1073\/pnas.98.2.658","article-title":"Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus\/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans","volume":"98","author":"Igarashi","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib127","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/CMR.10.2.358","article-title":"Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infection","volume":"10","author":"Weissman","year":"1997","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/smim.1993.1019","article-title":"The role of lymphoid organs in the pathogenesis of HIV infection","volume":"5","author":"Pantaleo","year":"1993","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol Dis"},{"issue":"2-3","key":"10.1016\/j.xphs.2016.09.015_bib130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-Glycoprotein, a gatekeeper in the blood-brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib131","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.antiviral.2008.12.013","article-title":"The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research","volume":"82","author":"Varatharajan","year":"2009","journal-title":"Antivir Res"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib132","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1172\/JCI2575","article-title":"HIV-1 protease inhibitors and the MDR1 multidrug transporter","volume":"101","author":"Lee","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.xphs.2016.09.015_bib133","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/bi972709x","article-title":"HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter","volume":"37","author":"Lee","year":"1998","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib134","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2007.31","article-title":"Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system","volume":"65","author":"Letendre","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.xphs.2016.09.015_bib135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","article-title":"Nanoparticle delivery of cancer drugs","volume":"63","author":"Wang","year":"2012","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib136","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib137","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addr.2009.03.009","article-title":"Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib138","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1023\/A:1015852732512","article-title":"Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting","volume":"9","author":"Schafer","year":"1992","journal-title":"Pharm Res"},{"issue":"5-6","key":"10.1016\/j.xphs.2016.09.015_bib139","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0928-0197(94)90058-2","article-title":"Influence of HIV-infection on the phagocytic activity of monocytes\/macrophages and granulocytes","volume":"1","author":"Schafer","year":"1994","journal-title":"Clin Diagn Virol"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib140","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1128\/AAC.40.6.1467","article-title":"Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes\/macrophages in\u00a0vitro","volume":"40","author":"Bender","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"1-3","key":"10.1016\/j.xphs.2016.09.015_bib141","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0168-3659(97)00105-3","article-title":"Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats","volume":"50","author":"Lobenberg","year":"1998","journal-title":"J\u00a0Control Release"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib142","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1023\/A:1011050209986","article-title":"Targeting of 3'-azido 3'-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues","volume":"18","author":"Dembri","year":"2001","journal-title":"Pharm Res"},{"issue":"14","key":"10.1016\/j.xphs.2016.09.015_bib143","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1073\/pnas.89.14.6477","article-title":"Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in\u00a0vitro and in\u00a0vivo studies","volume":"89","author":"Magnani","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib144","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/47.6.819","article-title":"Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus","volume":"47","author":"Rossi","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/nnm.16.1","article-title":"Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV\/AIDS","volume":"11","author":"Shao","year":"2016","journal-title":"Nanomedicine (Lond)"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib146","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.xphs.2016.09.015_bib147","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00126334-200312010-00005","article-title":"Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques","volume":"34","author":"Kinman","year":"2003","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"17","key":"10.1016\/j.xphs.2016.09.015_bib148","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000000421","article-title":"Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood","volume":"28","author":"Freeling","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib149","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.09.015_bib150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0005-2736(00)00254-6","article-title":"Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1","volume":"1468","author":"Bestman-Smith","year":"2000","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib151","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0005-2736(01)00432-1","article-title":"Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes","volume":"1558","author":"Gagne","year":"2002","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib152","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1211\/jpp\/61.06.0004","article-title":"Synthesis of methoxypoly(ethylene glycol) carbonate prodrugs of zidovudine and penetration through human skin in\u00a0vitro","volume":"61","author":"N'Da","year":"2009","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"12","key":"10.1016\/j.xphs.2016.09.015_bib153","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1086\/498310","article-title":"Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma","volume":"41","author":"Antinori","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.xphs.2016.09.015_bib154","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3181\/00379727-147-38444","article-title":"Lipid solubility and drug penetration of the blood brain barrier","volume":"147","author":"Oldendorf","year":"1974","journal-title":"Proc Soc Exp Biol Med"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0378-5173(98)00012-X","article-title":"Targeted drug delivery to the brain via phosphonate derivatives II. Anionic chemical delivery system for zidovudine (AZT)","volume":"166","author":"Somogyi","year":"1998","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2016.09.015_bib156","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.36.10.2156","article-title":"Central nervous system targeting of 2',3'-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs","volume":"36","author":"Morgan","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib157","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control"},{"issue":"7","key":"10.1016\/j.xphs.2016.09.015_bib158","first-page":"2849","article-title":"Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein","volume":"9","author":"Kemper","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.xphs.2016.09.015_bib159","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ejca.2004.01.024","article-title":"Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein","volume":"40","author":"Kemper","year":"2004","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib160","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15144-6","article-title":"Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes","volume":"28","author":"Choo","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib161","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/dmd.30.5.479","article-title":"Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats","volume":"30","author":"Savolainen","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib162","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0169-409X(02)00047-9","article-title":"Pluronic block copolymers for overcoming drug resistance in cancer","volume":"54","author":"Kabanov","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"2-3","key":"10.1016\/j.xphs.2016.09.015_bib163","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0168-3659(02)00009-3","article-title":"Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery","volume":"82","author":"Kabanov","year":"2002","journal-title":"J\u00a0Control Release"},{"issue":"5","key":"10.1016\/j.xphs.2016.09.015_bib164","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.jcbfm.9600414","article-title":"Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis","volume":"27","author":"Spitzenberger","year":"2007","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"issue":"1-2","key":"10.1016\/j.xphs.2016.09.015_bib165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneuroim.2008.06.009","article-title":"Ingress of blood-borne macrophages across the blood-brain barrier in murine HIV-1 encephalitis","volume":"200","author":"Liu","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.xphs.2016.09.015_bib166","first-page":"3393","article-title":"Comparative manufacture and cell-based delivery of antiretroviral nanoformulations","volume":"6","author":"Balkundi","year":"2011","journal-title":"Int J Nanomedicine"},{"issue":"17","key":"10.1016\/j.xphs.2016.09.015_bib167","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0b013e328357f5ad","article-title":"Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice","volume":"26","author":"Dash","year":"2012","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib168","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.virol.2006.08.012","article-title":"Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages","volume":"358","author":"Dou","year":"2007","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.xphs.2016.09.015_bib169","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/nnm.11.27","article-title":"Macrophage endocytic trafficking of antiretroviral nanoparticles","volume":"6","author":"Kadiu","year":"2011","journal-title":"Nanomedicine (Lond)"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib170","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2010.11.019","article-title":"Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages","volume":"150","author":"Nowacek","year":"2011","journal-title":"J\u00a0Control Release"},{"issue":"8","key":"10.1016\/j.xphs.2016.09.015_bib171","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/nnm.09.71","article-title":"NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery","volume":"4","author":"Nowacek","year":"2009","journal-title":"Nanomedicine (Lond)"},{"issue":"10","key":"10.1016\/j.xphs.2016.09.015_bib172","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/infdis\/jis395","article-title":"Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice","volume":"206","author":"Roy","year":"2012","journal-title":"J\u00a0Infect Dis"},{"issue":"8","key":"10.1016\/j.xphs.2016.09.015_bib173","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2006-03-012534","article-title":"Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery","volume":"108","author":"Dou","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.xphs.2016.09.015_bib174","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4049\/jimmunol.0900274","article-title":"Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS","volume":"183","author":"Dou","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"10.1016\/j.xphs.2016.09.015_bib175","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nmat4355","article-title":"A\u00a0pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices","volume":"14","author":"Zhang","year":"2015","journal-title":"Nat Mater"},{"issue":"2","key":"10.1016\/j.xphs.2016.09.015_bib176","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0168-3659(03)00203-7","article-title":"Expandable gastroretentive dosage forms","volume":"90","author":"Klausner","year":"2003","journal-title":"J\u00a0Control Release"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916417090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916417090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:59:49Z","timestamp":1749664789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916417090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":176,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0022354916417090"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2016.09.015","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Past, Present, and Future Drug Delivery Systems for Antiretrovirals","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2016.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}